Suppr超能文献

近年来,软骨素酶 ABC 在治疗中的应用取得了新进展。

Recent advances in the therapeutic uses of chondroitinase ABC.

机构信息

Department of Physiology, Development and Neuroscience, University of Cambridge, UK.

Laboratory for Neuroregeneration, Netherlands Institute for Neuroscience, Amsterdam, the Netherlands.

出版信息

Exp Neurol. 2019 Nov;321:113032. doi: 10.1016/j.expneurol.2019.113032. Epub 2019 Aug 6.

Abstract

Many studies, using pre-clinical models of SCI, have demonstrated the efficacy of chondroitinase ABC as a treatment for spinal cord injury and this has been confirmed in laboratories worldwide and in several animal models. The aim of this review is report the current state of research in the field and to compare the relative efficacies of these new interventions to improve outcomes in both acute and chronic models of SCI. We also report new methods of chondroitinase delivery and the outcomes of two clinical trials using the enzyme to treat spinal cord injury in dogs and disc herniation in human patients. Recent studies have assessed the outcomes of combining chondroitinase with other strategies known to promote recovery following spinal cord injury and new approaches. Evidence is emerging that one of the most powerful combinations is that of chondroitinase with cell transplants. The particular benefits of each of the different cell types used for these transplant experiments are discussed. Combining chondroitinase with rehabilitation also improves outcomes. Gene therapy is an efficient method of enzyme delivery to the injured spinal cord and circumvents the issue of the enzyme's thermo-instability. Other methods of delivery, such as via nanoparticles or synthetic scaffolds, have shown promise; however, the outcomes from these experiments suggest that these methods of delivery require further optimization to achieve similar levels of efficacy to that obtained by a gene therapy approach. Pre-clinical models have also shown chondroitinase is efficacious in the treatment of other conditions, such as peripheral nerve injury, stroke, coronary reperfusion, Parkinson's disease and certain types of cancer. The wide range of conditions where the benefits of chondroitinase treatment have been demonstrated reflects the complex roles that chondroitin sulphate proteoglycans (its substrate) play in health and disease and warrants the enzyme's further development as a therapy.

摘要

许多使用 SCI 临床前模型的研究已经证明了软骨素酶 ABC 作为脊髓损伤治疗的有效性,这一结果已在世界范围内的实验室和几种动物模型中得到证实。本综述的目的是报告该领域的研究现状,并比较这些新干预措施在急性和慢性 SCI 模型中改善结果的相对疗效。我们还报告了新的软骨素酶递送方法,以及两项临床试验的结果,这些试验使用该酶治疗犬的脊髓损伤和人类患者的椎间盘突出。最近的研究评估了软骨素酶与其他已知可促进脊髓损伤后恢复的策略相结合的结果,以及新方法。有证据表明,最有效的组合之一是软骨素酶与细胞移植相结合。讨论了用于这些移植实验的每种不同细胞类型的特定益处。将软骨素酶与康复相结合也可以改善结果。基因治疗是将酶递送到损伤脊髓的有效方法,并且避免了酶的热不稳定性问题。其他递送方法,如通过纳米颗粒或合成支架,已经显示出前景;然而,这些实验的结果表明,这些递送方法需要进一步优化,以达到与基因治疗方法相似的疗效水平。临床前模型还表明,软骨素酶在治疗其他疾病(如周围神经损伤、中风、冠状动脉再灌注、帕金森病和某些类型的癌症)方面也是有效的。软骨素酶治疗的益处已在广泛的疾病中得到证实,这反映了硫酸软骨素蛋白聚糖(其底物)在健康和疾病中所起的复杂作用,这证明了该酶作为一种治疗方法值得进一步开发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验